Fabhalta Capsules Specified Drug-use Survey

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

CHART-C3G/CLNP023B12011

NCT07331259 ·Status: NOT_YET_RECRUITING

A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.

NCT00312767 ·Status: WITHDRAWN ·Phase: PHASE4

Daratumumab in Treatment of PGNMID and C3 GN

NCT03095118 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

NCT05515458 ·Status: COMPLETED ·Phase: PHASE1

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

NCT07187401 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

NCT01000961 ·Status: COMPLETED ·Phase: PHASE3

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

NCT05517980 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

NCT01730469 ·Status: COMPLETED ·Phase: PHASE1

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

NCT01197378 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

NCT05468749 ·Status: COMPLETED ·Phase: PHASE1

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

NCT03301467 ·Status: COMPLETED ·Phase: PHASE2

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

NCT01733316 ·Status: COMPLETED ·Phase: PHASE3

Permeability Factor in Focal Segmental Glomerulosclerosis

NCT00007475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

NCT00872729 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

NCT03703908 ·Status: TERMINATED ·Phase: PHASE2

Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance

NCT02969200 ·Status: COMPLETED

Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome

NCT06797609 ·Status: ACTIVE_NOT_RECRUITING

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381 ·Status: COMPLETED ·Phase: PHASE1

A Study of CCX140-B in Subjects With FSGS

NCT03536754 ·Status: COMPLETED ·Phase: PHASE2

A Study With Imlifidase in Anti-GBM Disease

NCT05679401 ·Status: TERMINATED ·Phase: PHASE3

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of GCS-100 to Treat Chronic Kidney Disease

NCT01717248 ·Status: COMPLETED ·Phase: PHASE1

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT00782561 ·Status: TERMINATED ·Phase: PHASE1

Antiproteinuric Agents and Fabry Disease

NCT00343577 ·Status: COMPLETED